Table 1.

Association between risk factors and polypharmacy

	Mono Pharmacy (n = 49)		Poly Pharmacy (n = 54)		Unadjusted OR	df	P Value	Adjusted ORa	95% CI for OR		P Value
	n	%	n	%
Demographic
Gender
Male	25	24.3	31	30.1	1.2	1	0.5	1.2	0.5	2.7	0.6
Female	24	23.3	23	22.3
Illness
Diagnosis
Psychosis	24	23.3	12	11.7	1.4	1	0.2	1.6	0.8	3.2	0.1
Mood	20	19.4	35	34
Others	5	4.9	7	6.8
Comorbidity
Yes	29	28.2	35	34	1.2	1	0.5	1.3	0.6	3.0	0.4
No	20	19.4	19	18.4
Psychotic symptom
Yes	27	26.2	33	32	1.2	1	0.5	1.2	0.5	2.8	0.5
No	22	21.4	21	20.4
Treatment
Nonpharmacological
Yes	33	32	17	16.5	4.5	1	0.001	4.7	2.0	11.1	0.001
No	16	15.5	37	35.9
PRN medication
Yes	19	18.7	8	7.8	3.6	1	0.007	3.3	1.2	8.8	0.01
No	30	29.1	46	44.7
Physical restraint
Yes	39	37.9	32	31.1	0.4	1	0.02	0.3	0.1	0.8	0.02
No	10	20.4	22	40.7
Side effect
Yes	35	18.4	27	21.4	1.5	1	0.3	1.9	0.7	4.7	0.2
No	19	34	22	26.2

^a Adjusted for age, number of days as inpatient, amount of antipsychotic in chlorpromazine equivalent.